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Retinoic acid (RA) is the active metabolite of vitamin A but is also used as a medication,
primarily for acne in which the treatment regime lasts several months. A number
of studies have indicated that treatment with RA over this time period impacts the
hypothalamic-pituitary-adrenal (HPA) axis and may contribute to a number of the
side-effects of the drug. No studies though have investigated the short-term, early effects
RA may have on the HPA axis via the transcriptional pathways activated by the RA
receptor. This study investigated the action of RA over 3 days on regulatory components
of the HPA axis. Several key genes involved in glucocorticoid feedback pathways in the
hippocampus, hypothalamus and pituitary were unchanged after 3-days exposure to
RA. Key elements though in the adrenal gland involved in corticosterone and aldosterone
synthesis were altered in particular with the Cyp11b2 gene downregulated in vivo and
ex vivo. The rapid, 5 h, change in Cyp11b2 expression suggested this activation may be
direct. These results highlight the adrenal gland as a target of short-term action of RA
and potentially a trigger component in the mechanisms by which the long-term adverse
effects of RA treatment occur.
Keywords: retinoic acid, hypothalamic pituitary adrenal axis, corticosterone, aldosterone synthesis, adrenal gland,
Cyp11b1, Cyp11b2
INTRODUCTION
Isotretinoin, the 13-cis isomer of retinoic acid (RA), is an effective oral treatment for severe acne
first approved in the US, with FDA approval in 1982 (Layton, 2009). Its success resulted in wide
usage and it is reported that by 2011 20 million patients had taken it worldwide (Lowenstein and
Lowenstein, 2011). Early studies suggested that isotretinoin did not affect hormone levels (Palatsi
et al., 1997), but subsequent investigation revealed that, to the contrary, its effects on hormone
balance were broad with a complex array of effects over a typical 3-month treatment regime.
Isotretinoin was reported to repress level of numerous hormones (Karadag et al., 2015), reducing
adrenocorticotropic hormone (ACTH), cortisol, luteinizing hormone, prolactin, thyroid hormone
and testosterone, as well as growth factors such as insulin-like growth factor-binding protein 3,
insulin-like growth factor 1 (IGF-1) and growth hormone (GH). The effects were sufficiently strong
for isotretinoin to be considered a potential treatment for Cushing’s syndrome (Vilar et al., 2016).
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Given these wide-ranging hormonal effects, it is perhaps
unsurprising that up to 90% of patients taking isotretinoin
reported at least one side effect (Bremner et al., 2012). Depression
has been one adverse effect associated with isotretinoin treatment
(Bremner and McCaffery, 2008), a side-effect contentious ever
since the drug was first marketed and for which controversy
still continues (Oliveira et al., 2018). Research to determine a
plausible cellular and molecular mechanism has pointed to the
contribution of reduced hippocampal neurogenesis (Crandall
et al., 2004) and, more recently, induction of the hypothalamic-
pituitary-adrenal (HPA) axis given the link between HPA
axis hyperactivity and depression (Pariante and Lightman,
2008). Several studies on the chronic effects of RA have
suggested that this drug can induce hyperactivity of the HPA
axis (Cai et al., 2010). Long-term exposure to RA results in
significantly increased expression of corticotrophin-releasing
hormone receptor 1 (CRHR1), estrogen receptor-β (ERβ) and
mineralocorticoid receptor (MR) in the hypothalamus, three
genes involved in the activation of corticotrophin-releasing
hormone (CRH) neurons while the ratio of GRα/MR declines
(Cai et al., 2015).
To date the focus of research has been on the chronic effects
of RA on the body, acting over several weeks or months (Karadag
et al., 2015). No study has examined the short-term effects of
RA as a regulator of gene expression; the primary action of RA
is via retinoic acid receptors (RARs) which are ligand-activated
transcription factors. The present study investigated the effect of
RA over 3 days on the HPA axis of the adult rat and found that
early effects on the HPA axis in the adult were primarily directed
to the adrenal gland.
MATERIALS AND METHODS
Animals
The in vivo studies used 8-week-old, Sprague–Dawley male
rats (Charles River) which were randomly divided into a
treatment group (n = 5) and a control group (n = 5). For the
ex vivo experiments, adrenal glands were taken from 14 male
Sprague–Dawley pups (9–10 days old), which were euthanized
by a lethal intraperitoneal injection of pentobarbital. The pups
were decapitated before the adrenal glands were removed. The
adult rats were group-housed with three animals per cage with
free access to food and water. The pups were used prior to
weaning and therefore were housed with the dam. The humidity-
and temperature-controlled vivarium was maintained on a 12-h
light/dark cycle (lights on 7 am). All animal procedures were
carried out in accordance with HomeOffice regulations and local
ethics committee guidelines.
Drug Preparation and Treatments
A 0.1M (30mg/ml) solution of all-transRA in dimethyl sulfoxide
(DMSO) was prepared and stored in the dark at −70◦C until
required. On the day of use, 1 ml of 0.1M RAwas diluted in 29 ml
of Dulbecco’s Modified Eagle’s Medium (DMEM) containing
10% fetal calf serum (FCS) to make a 1 mg/ml RA solution
(Luo et al., 2004). The solution was stored in the dark until
administration. The vehicle-only control solution consisted of
1 ml DMSO diluted in 29 ml DMEM + 10% FCS.
In vivo Studies
RA was administered via an intraperitoneal route and 8-weeks
old rats were given either 1 mg/kg, 10 mg/kg RA or an equivalent
volume of DMSO-only control (n = 5 rats per treatment group).
Rats were given either a single injection of RA/vehicle, or an
injection once per day for three consecutive days. Injections
were carried out in the morning and rats were then sacrificed
5 h after the final injection. Rats were euthanized by CO2
inhalation. Euthanasia was followed by cervical dislocation and
the hippocampus, hypothalamus, pituitary and one of the adrenal
glands were removed and stored at−70◦C until processed.
Ex vivo Studies
Rats were killed with Euthatal and a single adrenal gland
from each rat was harvested immediately upon death. The
adrenal gland was stored in a dish with culture medium
(DMEM/F12, Gibco) on ice and taken for detailed dissection
within approximately 1 h. The surrounding adipose tissue was
removed from the adrenal gland under the microscope and each
adrenal was cut in half to provide a within-animal control set.
Each half-adrenal was transferred into a 24-well plate in 1 ml of
culture medium (DMEM/F12 plus 10% FCS) and placed at 37◦C,
5% CO2 for 2 h.
The adrenals were then treated with 1µMRAor an equivalent
concentration of DMSO (0.1%) for 5 h. Following treatment, the
adrenals were removed from the wells and stored individually at
−70◦C before analysis.
Quantitative PCR
Total RNA was extracted using an RNeasy mini kit (Qiagen)
with on-column RNase-Free DNase treatment (Qiagen).
Complementary DNA (cDNA) was synthesized from 500 ng
total RNA using a qScriptTM cDNA Synthesis Kit (CAT# 95047-
100, Quanta BiosciencesTM). As yields from the cultured adrenal
tissue were low, RNA was concentrated by ethanol precipitation
before cDNA synthesis. Quantitative real-time PCR (qRT-PCR)
was performed using the SensiMix SYBRmaster mix (Bioline) on
a Roche LightCycler 480. The primers used for qPCR are listed
in Table 1. Primers were designed using Primer-BLAST1 and
synthesized by PrimerDesign Ltd or Sigma-Aldrich. Actb was
used as the reference gene for all samples. All samples were run
in triplicate, along with standard curves prepared from a 5-fold
dilution of the stock cDNA samples mixed together and blanks.
qPCR analysis was performed using relative quantification on
Roche LightCycler 480 Software 1.5.1.
SDS-PAGE and Western Blotting Analysis
Tissues were homogenized in a buffer consisting of 150 mM
NaCl, 1% Triton, 0.1% SDS, 50 mM HEPES and protease
inhibitors (Roche). Protein concentrations were measured by
BCA assay (ThermoFisher Scientific, Waltham, MA, USA). 50µg
of protein was loaded and separated on 12% SDS-polyacrylamide
gels and then transferred onto Hybond-ECL nitrocellulose
1https://www.ncbi.nlm.nih.gov/tools/primer-blast/
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TABLE 1 | Genes and primer sequences for qPCR.
Gene Product size (bp) Primer sequence (5′-3′)
Rarb 134 F-ACACCACGAATTCCAGCGCTGAC
R- CAGACCTGTGAAGCCCGGCA
Actb 112 F- CCACACCCGCCACCAGTTCG
R- TACAGCCCGGGGAGCATCGT
Nr3c2 83 F- CGTGCGGCTTCAGCTGACCT
R- TGAGGCCATCTTTTGGAACTGTGCTC
Fkbp5 150 F- CGTGTGCCAGAGGAAGGCGA
R- TGTTTCTTGCCGGCCGCTCC
Hsd11b1 121 F- TCACTGGGGCCAGCAAAGGGAT
R- AGGCAGCGAGACACCACCTTCTG
Crh 132 F- CTGCCAAGGGAGGAGAAGAGAGCG
R- TCCAGAGACGGATCCCCTGCTCA
Nr3c1 150 F- GCTGGAGGTGATTGAACCCGAGG
R- CTGAAGCCTGGTATCGCCTTTGCC
Pomc 216 F- GCCTTTCCGCGACAGGGGTC
R- AAGCCCGGATGCAAGCCAGC
Pcsk1 100 F- GTGCAAGCTGGGGCCCTAATGA
R- CCTTGTCTCCCCTGTTTGACACCG
Pcsk2 137 F- GAATCCCGAGGCCGGTGTGG
R- GCCAGGTCAGATCCACGTTAGCC
Cyp11b1 145 F-GGAGTGTCATATCCGAGATGGTAGCAC
R- TCTGGGTTCCGAGCCAGCTCAA
Cyp11b2 122 F- TGGGTGGCCCACAGGGAACTC
R- TTTTGAACAGCTTTTGGTGACAGCACG
membranes (Amersham Protran Premium 0.45 µm NC) using
a Mini Trans-Blot Cell (Bio-Rad). The membranes were blocked
with 5% skimmed milk in Tris-buffered saline containing 0.05%
Tween-20 (TBST) for 1 h at room temperature. The blots
were incubated overnight in primary antibody, against either
CYP11B1 (1:300; MAB6020, Millipore) or CYP11B2 (1:1,000;
anti-C11B2 antibody, Abcam) diluted in TBST containing 2%
BSA at 4◦C. The following day, the blots were washed three
times with TBST before incubating with horseradish peroxidase-
conjugated secondary antibody at 1:3,000 dilution in TBST
containing 5% skimmed milk, using anti-mouse secondary
antibody (Millipore) for CYP11B1 or anti-rabbit secondary
antibody (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA) for CYP11B2, each incubated for 1 h at room
temperature. The membranes were then washed three times
for 5 min in TBST and incubated at room temperature for
2 h with HRP-conjugated anti-β-actin (1:50,000, Sigma). After
three washes in TBST for 5 min, the blots were then developed
using enhanced chemiluminescence substrate (Millipore) and the
protein bands for CYP11B1 or CYP11B2 together with β-actin
were imaged simultaneously using a MyECL Imager (Thermo
Scientific Fisher, Waltham, MA, USA). Band intensities were
quantified from images using ImageJ software 1.47v.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Corticosterone and aldosterone levels in serum were measured
by ELISA (CAT# KGE009 and KGE016, R&D Systems Biotechne
for corticosterone and aldosterone, respectively). Serum samples
were stored at −70◦C, thawed and 150 µl of blood serum
treated with 150 µl of pretreatment reagent supplied with the
kit, incubated at room temperature for 15 min and subsequently
centrifuged at 12,000 g for 4 min. All other steps were performed
according to the manufacturer’s protocol and the microplate was
read at 450 nm and 560 nm on a Precision Microplate Reader
(Molecular Devices, San Jose, CA, USA) using the SoftMax Pro v
5.2 software.
Statistical Analysis
All data are expressed as Mean ± standard error of the
mean (SEM). Statistical analyses were performed using the
IBM SPSS Statistic v 25 program and graphical presentation
of data used Microsoft Office Excel 2018. All groups of
samples were subjected to normal distribution test using the
Kolmogorov–Smirnov test and samples set at 100%.
For the 5-h ex vivo experiment, the cultured adrenals and
the 3 days in vivo experiment were analyzed using a two-tailed
Student’s t-test. However, the 3 days dose concentration
experiment were analyzed using a one-way analysis of variance
(ANOVA) with Dunnett’s multiple comparison test.
The degree of significance value (p-value) less than
p < 0.05 was considered statistically significant. A p-value
less than 0.05 was designated with one asterisk (∗), p ≤
0.01 designated with two asterisks (∗∗), p ≤ 0.001 designated
with three (∗∗∗) and p ≤ 0.0001 designated with four (∗∗∗∗).
RESULTS
Given the known response of the HPA axis to chronic (6 weeks
to 3 months) treatment with RA (Cai et al., 2010; Vilar et al.,
2016), this study investigated whether a short duration (3 days)
of RA treatment (10 mg/kg) may bring about relatively rapid
changes in the regulatory components of the HPA axis. This
amount of RA was chosen to be equivalent to the high dose
treatment used therapeutically for acne (Cyrulnik et al., 2012)
which is a mean dose of 1.6 mg/kg per day, taking into account
allometric scaling for conversion between species based on body
surface area (Nair and Jacob, 2016). This was compared to
a low dose of 1 mg/kg of RA. In addition to the HPA axis,
the effect of RA on the hippocampus was assessed as it may
regulate HPA axis activity via feedback on to the hypothalamus
(Jacobson and Sapolsky, 1991).
In the hippocampus, the two receptors crucial for
glucocorticoid negative feedback were investigated; the
mineralocorticoid receptor (MR, encoded by Nr3c2) and
the glucocorticoid receptor (GR, Nr3c1; McEwen et al., 1992).
In addition, the gene for the GR co-chaperone FK506 binding
protein 51 (Fkbp5; Hähle et al., 2019) which has been implicated
in modulating GR sensitivity, was measured together with
11β-hydroxysteroid dehydrogenase type 1 (Hsd11b1, Wyrwoll
et al., 2011) encoding an enzyme converting cortisone to
active corticosterone. However, none of these genes, key to
the modulation of glucocorticoid signaling, were influenced by
short-term activation of RA signaling (Figure 1A). In contrast,
the dose-dependent positive induction of RA receptor beta gene
(Rarb), known to be highly responsive to RA (Sucov et al., 1990),
demonstrated that RA reaches the hippocampus and that the
cellular machinery required for a transcriptional response is
present (Figure 1A).
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FIGURE 1 | The influence of 3-day 1 mg/kg or 10 mg/kg retinoic acid (RA) treatment of the rat on mRNA expression levels in the (A) hippocampus, (B)
hypothalamus and (C) pituitary gland. The Rarb positive control was the only gene to show a statistically significant change in the three tissues (p < 0.001 in all
cases) indicated by ∗. All control values were normalized to 100%. Panel A; n = 6 RA, n = 6 control; panel B; n = 6 RA, n = 6 control and panel C; n = 5 RA,
n = 5 control. ∗ = p < 0.05 , ∗∗ = p < 0.01, ∗∗∗∗ = p < 0.0001.
A similar set of glucocorticoid regulatory genes were
investigated in the hypothalamus following the same short-term
treatment with RA, examining Nr3c2, Fkbp5, Hsd11b1 as well
as the gene encoding corticotropin-releasing hormone (Crh;
Figure 1B), produced by the hypothalamus to induce ACTH
release by the pituitary gland. Again, however, RA did not
influence the expression of these genes in the hypothalamus,
whereas the Rarb positive control was induced equally by 1 and
10 mg/kg RA. Finally, in the brain the influence of such RA
treatment was investigated on the pituitary gland, determining
the expression of Nr3c2, Fkbp5 as well as proopiomelanocortin
(Pomc), encoding the precursor of ACTH and the genes encoding
the enzymes that cleave POMC, prohormone convertase 1
(PC1 protein, Pcsk1 gene) and 2 (PC2 protein, Pcsk2 gene;
Figure 1C; Harno et al., 2018). As in the hippocampus
and the hypothalamus, there were no significant changes in
these genes in RA-treated rats, in contrast to the significant
induction of the Rarb positive control by 10 mg/kg RA,
however a downregulation of Rarb was evident at 1 mg/kg
RA (Figure 1C).
The influence of short-term RA treatment on gene expression
was then investigated in the adrenal gland, the final component
of the HPA axis, quantifying genes required for the synthesis
of stress-regulating hormones. mRNA levels of the genes
encoding the enzymes that catalyze the final rate-limiting step
in corticosterone synthesis (Cyp11b1) and the synthesis of
aldosterone from the same substrate (Cyp11b2; Schiffer et al.,
2015) were measured by qPCR. 10 mg/kg RA induced a
strong and significant repression of Cyp11b2 and the Rarb
positive control was induced by the same dose although
again a downregulation of Rarb was evident at 1 mg/kg
RA (Figure 2A). To determine whether RA had a rapid
effect on these genes rats were treated with 10 mg/kg RA
for just 5 h and this resulted in a significant reduction of
Cyp11b2 (Figure 2B). To determine if this influence was direct,
independent of factors outside the adrenal gland, the tissue
was removed, cultured ex vivo and the influence of RA studied
after just 5 h (Figure 2C). Cyp11b2 was again significantly
repressed by RA treatment implying a direct rapid effect of
RA on this gene, as is known to occur for RA induction of
Rarb (Figure 2C).
Protein expression of CYP11B1 and CYP11B2 was
then examined after 3 days of RA treatment and
CYP11B1 significantly increased with the application of
RA (Figure 3A). In contrast, there was no significant
change in CYP11B2 protein. Finally, plasma aldosterone and
corticosterone were measured by ELISA to determine whether
changes in these glucocorticoid-synthesizing enzymes in the
adrenal gland translated into changes in blood hormone levels.
The unexpected result was the lack of change in aldosterone
and a decrease in corticosterone levels (Figures 3B,C) after RA
treatment implying the action of RA on other mechanisms of
control in addition to the changes in these synthetic enzymes.
DISCUSSION
The long-term influence of RA on the HPA axis has previously
been examined from two perspectives; one as a treatment
of Cushing’s disease (Vilar et al., 2016), and second as a
possible contributor to depression (Cai et al., 2010, 2015; Hu
et al., 2013). In the former, RA treatment over several months
suppresses the HPA axis due to decreased ACTH secretion
as a result of inhibition of pituitary gland POMC expression.
The latter showed that approximately 3-weeks of RA exposure
induces HPA activity, with increased CRH in the hypothalamic
paraventricular nucleus (PVN) and decreased GR protein levels
in the hypothalamus (Hu et al., 2013; Cai et al., 2015).
The present study contrasted these long-term actions with the
short-term (3-day) effects of RA in the adult rat to indicate what
may be the initial targets of RA in the HPA axis. The results paint
another picture again of the action of RA on this axis with an
apparent direct action on the adrenal gland. It was shown that RA
reached all tissues of the HPA axis as demonstrated by induction
of the RA-responsive gene Rarb. Many key genes involved in the
HPA axis did not change with this treatment including those
encoding the corticosteroid hormone receptors, CRH, as well as
POMC and the enzymes processing POMC protein together with
the 11β-HSD1 enzyme. The only early significant effect in the
components of the HPA system examined in the adult rat was
in the adrenal gland in which the Cyp11b2 gene encoding the
enzyme that takes the corticosterone substrates to aldosterone
was rapidly down-regulated. That this is a direct effect is implied
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FIGURE 2 | The influence of in vivo and ex vivo RA treatment on adrenal gland Cyp11b1, Cyp11b2 and Rarb expression. (A) The relative effects of 1 mg/kg vs.
10 mg/kg dose of RA in the rat was compared on gene expression and there was no influence on Cyp11b1 at either dose (1 mg/kg RA, p = 0.882, 10 mg/kg RA,
p = 0.874) while Cyp11b2 was repressed at the higher dose (1 mg/kg RA, p = 0.188, 10 mg/kg RA, p = 0.018). Rarb was strongly induced by the 10 mg/kg RA
dose (p = 0.00009) but surprisingly repressed at 1 mg/kg RA (p = 0.048). (B) Five-hour treatment of the rat with RA resulted in significant induction of the Rarb
positive control in the adrenal gland and Cy11b2 fell in expression (p < 0.001 and p = 0.018, respectively). (C) Five-hour treatment with RA of an ex vivo adrenal
glands culture resulted in Rarb again increasing and Cyp11b2 falling in expression (p = 0.0188 and p = 0.0184, respectively). ∗ = p < 0.05 , ∗∗∗∗ = p < 0.0001.
by the rapid (5 h) effect of RA when treated in vivo and that
RA can directly induce this when applied to cultured rat adrenal
gland. At the 3-day time point examined however there was no
corresponding decrease in CYP11B2 protein. In contrast, there
was a significant increase in the CYP11B1 protein which catalyzes
the synthesis of corticosterone. Surprisingly, when the hormone
product of this enzyme, corticosterone, was measured in the
circulation, the levels did not reflect the increase in the synthetic
enzyme, rather there was a decline while the hormone product of
CYP11B2, aldosterone, remained unchanged.
Thus, RA treatment brings about three significant changes in
the adrenal gland related to corticosterone synthesis in levels of
transcript, protein and corticosterone itself, but the changes are
surprisingly disconnected. Although RA appears to have a rapid
influence on Cyp11b2 expression this is not translated into a
change in protein by 3 days. There are presumably compensatory
mechanisms preventing protein response and although it is
possible that protein may be decreased in the first day or two
this would be unlikely to bring significant change to the adrenal
gland. Intriguingly, the change in protein induced by RA was
in a gene that did not change in transcript levels and this may
indicate a direct effect of RA to regulate protein translation. This
function of RA, independent of gene transcription, is amongst
its repertoire of ‘‘non-genomic actions.’’ These actions include
regulation of mRNA translation via direct interaction of RARα
with transcript and binding of RA releasing mRNA to allow
its translation (Maghsoodi et al., 2008; Schwertz et al., 2017).
It may be conjectured that RA can regulate CYP26B1 through
such a mechanism. It is unknown whether the level of change is
sufficient to increase corticosterone synthesis and when serum
levels were measured a contrary decline in corticosterone was
evident. It is not immediately apparent how these shifts are
integrated but they may represent a view at a single time point
of 3 days of rapid fluctuations followed by feedback repression,
for instance, the decline in corticosterone at 3 days may be a
feedback response to an earlier increase. Such a rapid negative
feedback system is well-characterized in the HPA axis (Tasker
and Herman, 2011). This feedback suppresses the secretion of
CRH from neurons within the PVN of the hypothalamus. There
are a series of overlapping systems triggering this feedback
overlapping in time intervals with the fastest taking seconds to
minutes and the rapid actions of glucocorticoids are mediated
via non-genomic actions triggering various steps including a
G-protein coupled receptor rather than the slower transcriptional
regulatory route using the nuclear GR (Di et al., 2003). Such
non-genomic actions of GR are also proposed for the distinct
rapid negative feedback action glucocorticoids have on pituitary
production of ACTH (Deng et al., 2015). Such negative feedback
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FIGURE 3 | The influence of in vivo RA treatment on adrenal gland expression of CYP11B1 and CYP11B2 protein as well as serum aldosterone and corticosterone
levels. (A) Western blotting and band quantitation to determine the change in CYP11B1 and CYP11B2 relative to β-actin (imaged simultaneously) following in vivo RA
treatment showed a significant increase in CYP11B1 (p = 0.043) and no significant changes in CYP11B2 (p = 0.798). All control values were normalized to 100%.
(B) Quantitation of blood aldosterone levels with in vivo RA treatment indicated no significant change (p = 0.221) while (C) quantitation of blood corticosterone levels
indicated a significant decline in hormone after in vivo RA treatment (p = 0.049). Significance was indicated by ∗. N = 5 per treatment group in each case. ∗p < 0.05.
is crucial to prevent hormone depletion and is also protective
of harm from excess glucocorticoid exposure (Strelzyk et al.,
2012; Johnstone et al., 2019). A decline in this feedback results
in HPA hyperactivity and is a biological change frequently
linked with depression (Pariante and Lightman, 2008). The
multiple layers of feedback act to maintain correct levels of
corticosteroids under a wide range of physiological conditions.
These can be aberrantly disrupted though as a result of drug
treatment. The action of RA on the adrenal gland is rapid
and for instance, leads to a decrease in Cyp11b2 transcript
within 5 h. It will be presumed that any resulting change in
corticosterone will happen in less than 24 h and the early changes
as a result of RA treatment are expected to be an increase
in corticosterone. Rapid feedback inhibition is known to be a
response to increasing corticosterone concentrations, rather than
absolute concentration (Abe and Critchlow, 1977). It is possible
the result seen in this study at the 3-day period is the outcome
of negative feedback and a slight overcompensation leading to
a decline in corticosterone compared to controls. This can be
resolved with future studies refining the analysis of these early
changes and quantifying corticosterone in intervals up to 3 days.
Parallels may also exist in these responses with the changes seen
in Rarb expression, which generally responds with induction
of expression but decreases with 1 mg/kg RA treatment in the
pituitary and adrenal glands. This may be conjectured to be the
result of feedback decline at this particular dose perhaps similar
to the feedback response in RA signaling that can occur in the
embryo (Lee et al., 2012).
The complex action of RA on the HPA axis is evident
from long-term studies. Nineteen days of intracerebroventricular
injection of RA into the rat increases CRH and RARα in the
hypothalamus, as well as repressing GR and inducing a rise
in blood corticosterone (Hu et al., 2013). A further view into
the complication of the interactions of RA with the HPA axis
is evident if RA levels are dropped in the rat as a result of
10-week deficiency of substrate (vitamin A). In this case, blood
corticosterone rises, and 5-days of 0.15 mg/kg RA decreases
this back to control levels. With such treatment, there are no
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changes in expression in the genes for Nr3c2, Nr3c1 or Crh
in the hypothalamus, although Hsd11b1 rises when vitamin A
is depleted and falls back to control levels with RA treatment.
There are however changes in the hippocampus with vitamin A
deficiency, inducing decline in the genes for MR and GR and
decrease in Hsd11b1, all of which are restored by RA treatment
(Marissal-Arvy et al., 2013).
The actions of RA on the adrenal gland may contribute to
the range of side-effects found with RA when used as a drug,
evident from when it first entered the market in the early 80 s
for the treatment of acne. Although the most common effects
are not severe they are very wide-ranging including effects on
skin, muscle, bone, liver and central nervous system (CNS; Khalil
et al., 2017). The teratogenic effects of RA have a well-established
mechanistic basis but these other effects on the adult body are
not well understood in terms of mechanism. Action of RA on
the HPA axis could result in change in corticosteroid balance
and provide a mechanism for the diverse adverse effects on
multiple organs. As discussed earlier, an adverse effect of RA
on hormonal balance, including cortisol concentrations, has
previously been shown (Karadag et al., 2015). However, all
previous work has been on the long-term effects of RA and this
study is the first to show a rapid effect on the adrenal gland
which may be one of the primary factors to disrupt the entire
HPA axis. If there were a long-term reset of feedback in the
HPA axis this could contribute to an explanation for some of the
lasting adverse effects. For instance, joint pain, bone disease, skin
disorders and inflammatory bowel disease have been reported
to continue even after discontinuation of therapy (Brzezinski
et al., 2017), whereas the half-life of the drug is only 29 h
(Nulman et al., 1998).
To conclude, a high dose of RA, equivalent to that used
for high dose treatment of acne, does not affect transcript
levels in the short-term of several key genes of the neural
part of the HPA axis. However, a response is evident in the
adrenal gland where RA regulates Cyp11b2 transcription and
CYP11B1 protein levels in the adult adrenal gland which were
decreased and increased, respectively. The surprising net effect
of these changes is a decrease in circulating corticosterone at day
3, potentially the result of dynamic changes in corticosterone
over time with feedback compensation resulting in a decline
below normal levels. The results point to the early events
following RA treatment, inducing small independent changes in
various aspects of adrenal gland corticosteroid synthesis that may
underlie the long-term effects of either activation or repression of
the HPA axis with RA treatment (Cai et al., 2010, 2015; Hu et al.,
2013; Vilar et al., 2016) and place early events in the adrenal gland
as a key to these changes.
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